fbpx
All about COVID19 - An initiative from WhiteCoats that brings together updates from top curated resources exclusively for healthcare professionals

In a recent Phase II ESCAPE clinical trial in hospitals in Greece, the effects of anakinra and tocilizumab treatments in critically ill COVID-19 patients were studied. The study was conducted on patients screened with SOFA (Sequential Failure Organ Assessment score) ≥2  or ARDS, MAS (serum ferritin greater than 4,420ng/ml) and CID (serum ferritin  ≤4,420ng/ml). The Patients were treated with anakinra ...

In China, after the COVID-19 outbreak, the researchers have been testing a traditional Chinese medicine (TCM) for the disease diagnosis until prognosis. A recent study conducted by those researchers in China has found an effective treatment for Covid-19 patients with Weifen syndrome using a native Yinqiao powder. The Yinqiao powder consisting of active ingredients, such as rutin and hesperidin  might ...

Certain people with comorbidities are observed to be at a higher risk of developing severe illness. Previous reports showed that diabetes had a hazard ratio of 2:3 for mortality. Studies have also revealed that people with diabetes, in general, are at higher risk for other infections. In the current studies, 2877 patients with COVID-19 admitted to the hospital were investigated. ...

Researchers studying the effect of convalescent sera and monoclonal antibodies from recovered patients found the UK and South African SARS-CoV-2 variants are more resistant to neutralization compared to the wild-type virus. The research team used previously obtained blood samples from 20 COVID-19 patients after their recovery, to collect eight receptor-binding domain (RBD) specific monoclonal antibodies. They expressed the wild type ...

Sputnik V is a COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology. An interim analysis from the trial that was published in the Lancet indicating 91.6% efficacy without unusual side-effects. Sputnik V uses a heterologous recombinant adenovirus approach utilizing adenovirus 26 (Ad26) and adenovirus 5 (Ad5) as vectors for the expression of SARS-CoV-2 spike (S) protein. ...

Researchers have reported a 54-year-old COVID-19 patient who presented with SARS-CoV-2 elated pneumonia, posterior reversible encephalopathy syndrome (PRES), and persistent cortical blindness. At the time of hospital admission, the patient had a high body temperature, significantly elevated heart rate, and 82% oxygen saturation level. Because of further deterioration of the health condition of the patient, non-invasive ventilation was started. Because ...

A pre-print paper describes a chimpanzee adenovirus-vectored vaccine that, when administered intranasally in rhesus macaques, led to a robust immune response and demonstrated protection against infection by the virus that causes COVID-19. This vaccine is a chimpanzee Adenovirus (simian Ad-36)-based SARS-CoV-2 vaccine (ChAd-SARS-CoV-2-S) that expresses the S protein. Post-vaccination, the researchers found anti-S, anti-RBD, and neutralizing antibodies. T cell responses ...

Scientists have discovered that factors such as dysbiosis could influence the SARS-CoV-2 infection course. One can hypothesize that SARS-CoV-2 interacts with the gut microbiota via the gut/lung axis (a cross between the host and all the microbiota sites). With the viral entry into the host cell, leading to lung damage and the subsequent series of reactions that end in an ...

Researchers from the USA have conducted a study showing that Moderna's mRNA-1273 vaccine neutralizes all circulating variants of SARS-CoV-2 tested to date. Concerns have been raised with the increasing transmission rates and higher viral loads associated with the recently emerged B.1.1.7 (UK) and B.1.351 (South Africa) variants. There were also concerns that these strains may potentially circumvent immunity conferred by ...

A team of researchers from the USA and Sweden has recently demonstrated that increased levels of the proinflammatory cytokine, angiopoietin-2 (ANG2), is responsible for hypercoagulation observed in severe COVID-19 patients. In the current study, the scientists evaluated whether an elevated plasma level of ANG2 in critically ill COVID-19 patients can modulate the coagulation system by inhibiting thrombomodulin-mediated activation of protein ...